
Shivang Joshi, MD, MPH, RPh, FAHS, highlights Symbravo’s non-substitutability, multi-mechanistic design, and key safety considerations for pharmacists across care settings.

Shivang Joshi, MD, MPH, RPh, FAHS, highlights Symbravo’s non-substitutability, multi-mechanistic design, and key safety considerations for pharmacists across care settings.

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

Expert pharmacists discuss future outlooks for unit-based pharmacy models.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

Continuous glucose monitoring (CGM) via interstitial fluid, sweat, and saliva are less invasive than prior methods.

Pharmacists discuss educational opportunities and training opportunities for pharmacists interested in unit-based pharmacy models.


Emerging pharmacy trends will be highlighted at the American Society of Health-System Pharmacists (ASHP) Midyear 2025, including AI innovations, GLP-1 therapies, and evolving geriatric and neonatal care.

The FDA approves a new dose of Omlyclo, the first interchangeable biosimilar to Xolair, enhancing treatment options for allergic and inflammatory conditions.

Research reveals low-dose cannabinoids, like THC, may enhance serotonin levels and combat chronic inflammation in patients with HIV, offering new treatment possibilities.

Researchers explore how immune history and innovative vaccine technologies enhance protection against flu, highlighting pharmacists' vital role in patient education.

Implementing a best practice advisory into physicians’ electronic health records improved lipid therapy initiation and diagnoses of hyperlipidemia and hypercholesterolemia.

Shivang Joshi, MD, MPH, RPh, FAHS, outlines essential counseling points on dosing, timing, contraindications, and rebound headache risks when dispensing Symbravo.

Unit-based pharmacists discuss their crucial roles in advancing interdisciplinary care.


Pirtobrutinib’s indication was expanded for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, allowing for treatment in earlier lines of therapy.

The supplemental new drug application (sNDA) was assigned a PDUFA target action date of July 26, 2026.

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

A new rapid test for pertussis enables quick diagnosis in as little as 15 minutes, addressing rising whooping cough cases.



The pneumococcal 13-valent conjugate vaccine (PCV13) was effective at preventing pneumococcal lower respiratory tract infection (LRTI) in older patients from Thailand.

Unit-based pharmacists discuss the key contributions they make to the care team.

A panel of pharmacists discuss the innerworkings of unit-based pharmacy.

A cohort study of over 6 million US veterans revealed a 76% increased risk of pancreatic cancer following chronic hepatitis C infection.

A 3-month resistance exercise program helped improve walking distance, grip strength, and other parameters of physical health in patients with long COVID.

The blood test helps patients avoid unnecessary and invasive biopsies.

Depression and cardiometabolic disease share hormonal, inflammatory, and behavioral pathways requiring integrated pharmacist-led recognition and management.

Researchers reveal fibroblasts as key players in hidradenitis suppurativa inflammation, paving the way for innovative treatment strategies.

The FDA approves Amneal's albuterol sulfate inhalation aerosol, enhancing access to vital asthma and COPD treatments for millions of Americans.